Analystreport

Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) had its "buy" rating re-affirmed by analysts at Robert W. Baird. They now have a $30.00 price target on the stock.

Mirum Pharmaceuticals, Inc. - common stock  (MIRM) 
Last mirum pharmaceuticals, inc. - common stock earnings: 3/12 04:02 pm Check Earnings Report